BeOne Medicines (NASDAQ:ONC) received U.S. FDA approval for TEVIMBRA (tislelizumab) combined with ZIIHERA (zanidatamab) and chemotherapy as a first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.
Jazz Pharmaceuticals (NASDAQ:JAZZ) received U.S. Food and Drug Administration approval for two Ziihera (zanidatamab-hrii) treatment regimens for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.
Anavex Life Sciences (NASDAQ:AVXL) reported third fiscal quarter 2026 results and provided updates on blarcamesine development programs targeting Alzheimer’s disease, Rett syndrome, and Fragile X syndrome.
Vyome Holdings (NASDAQ:HIND) reported second-quarter 2026 results and provided a corporate update, highlighting progress on VT-1953, its lead program for symptoms associated with malignant fungating wounds.
OrthoPediatrics (NASDAQ:KIDS) announced the full commercial launch of its 3P Pediatric Plating Platform Hip System in the United States after a limited launch phase that included more than 350 surgical implantations.
BioCryst (NASDAQ:BCRX) announced that Japan’s Ministry of Health, Labor and Welfare approved once-daily ORLADEYO (berotralstat) as a preventive treatment for pediatric hereditary angioedema (HAE) patients aged 2 to under 12 years.
Sagimet Biosciences (NASDAQ:SGMT) reported progress on its AURORA U.S. Phase 3 clinical trial evaluating denifanstat, a FASN inhibitor being developed for moderate to severe acne.
McKesson (NYSE:MCK) agreed to acquire Precision Medicine Group for approximately $2.25 billion, adding clinical research and biopharma commercialization services to its oncology and multispecialty operations.
Summit Therapeutics (NASDAQ:SMMT) announced publication of primary analysis results from the Phase III HARMONi clinical trial, showing ivonescimab combined with chemotherapy improved progression-free survival in patients with EGFR-mutated advanced non-small cell lung cancer.
Johnson & Johnson (NYSE:JNJ) received U.S. Food and Drug Administration approval for IMAAVY (nipocalimab-aahu) as the first treatment specifically approved for warm autoimmune hemolytic anemia (wAIHA) in adults and pediatric patients aged 12 years and older.
Molecular Partners (NASDAQ:MOLN) reported first-half 2026 results and clinical progress across its oncology pipeline, including MP0712, a DLL3-targeting Radio-DARPin program for small cell lung cancer that advanced into the next trial cohort.
Rhythm Pharmaceuticals (NASDAQ:RYTM) received Japanese marketing authorization for its IMCIVREE therapy, targeting a company-estimated 5,000 to 8,000 obesity patients.
